RENÚ®’s advanced calcium-based technology promotes the growth of a patient’s own collagen.
RENÚ® CaHA based technology provides an aesthetic correction that has been shown to last longer.
RENÚ® Calcium Hydroxylapatite Implant is indicated as a soft tissue-bulking agent for vocal fold medialization, vocal fold insufficiency, subdermal implantation for the correction of moderate to severe facial wrinkles and folds and for the restoration or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus.
Current concepts in cosmetic appearance conclude that facial aging involves changes in skin quality, facial laxity, and in facial volume.3 Skin quality is treated with laser resurfacing and facial laxity is managed with lift procedures like face lifts. Facial volume can best be dealt with by injection treatments and this is better provided by high viscosity and higher yield strength products like the Calcium Hydroxylapatite Implant.
Collagen deposition continues with collagen slowly replacing first the the carrier gel and then the hydroxylapatite particles until remodeling is complete in about one (1) to two (2) years. While not being a 1:1 replacement, this tissue regeneration may account for the durable correction obtained in some of the patients. 3The primary facial areas that have been treated include the nasolabial folds, marionette lines, pre-jowl depressions, acne scars, malar, and other general soft tissue defects. The calcium hydroxyapatite acts to volumize and lift the treated site.
Calcium hydroxylapatite particles provide a matrix for collagen formation with the result being an implant that ends up closely resembling the surrounding tissue. Collagen deposition within a calcium hydroxylapatite implant is thought to begin with Type III collagen which is gradually replaced by Type I collagen in approximately six (6) months.
The needle should be placed at the subdermal plane or deep dermal levels. The injection technique can be by either single, fanning, or parallel tunnels of relatively small amounts of the calcium hydroxyapatite implant. The specific technique varies according to the nature of the defect. Linear layering in the subdermal plane is accomplished by manual molding for a smoother contour. Overcorrection should be avoided.
It is suggested that an area be corrected to the preferred outcome before treating another area as post-injection swelling may interfere with visualization. Multiple treatments may be needed to acquire optimal outcomes. Treatments require little administration time and often have most patients returning to their normal activities immediately after treatment.